Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;36(9):516-23.
doi: 10.1002/clc.22147. Epub 2013 May 30.

Landmark lipid-lowering trials in the primary prevention of cardiovascular disease

Affiliations
Review

Landmark lipid-lowering trials in the primary prevention of cardiovascular disease

Jonathan Chrispin et al. Clin Cardiol. 2013 Sep.

Abstract

Although atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality in the world, the long disease latency affords ample opportunity for preventive care. Indeed, lifelong exposure to atherogenic apoliprotein B-containing lipoproteins has consistently been shown to increase the cumulative risk of suffering a CVD event, including myocardial infarction, stroke, and symptomatic peripheral arterial disease. Over the past 25 years, lipid-lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse CVD events and CVD mortality. This review will highlight several key clinical trials encompassing several classes of lipid-lowering medications that have provided clinicians with an evidence-based framework for managing their patients' cardiovascular risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
LDL‐C reduction in landmark statin primary prevention trials. Abbreviations: AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ASCOT‐LLA, Anglo‐Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL‐C, low‐density lipoprotein cholesterol; LDL‐P, placebo arm low‐density lipoprotein cholesterol; LDL‐S, statin arm low‐density lipoprotein cholesterol; MEGA, Primary Prevention of Cardiovascular Disease with Pravastatin in Japan; WOSCOPS, West of Scotland Coronary Prevention Study.
Figure 2
Figure 2
Event rate in placebo vs statin arms in landmark statin primary prevention trials. Abbreviations: AFCAPS/TexCAPS‐P/AFCAPS/TexCAPS‐S, Air Force/Texas Coronary Atherosclerosis Prevention Study Placebo/Statin; ASCOT‐LLA‐P/ASCOT‐LLA‐S, Anglo‐Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm Placebo/Statin; JUPITER‐P/JUPITER‐S, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin Placebo/Statin; LDL‐C, low‐density lipoprotein cholesterol; LDL‐P, placebo arm low‐density lipoprotein cholesterol; LDL‐S, statin arm low‐density lipoprotein cholesterol; MEGA‐P/MEGA‐S, Primary Prevention of Cardiovascular Disease with Pravastatin in Japan Placebo/Statin; WOSCOPS‐P/WOSCOPS‐S, West of Scotland Coronary Prevention Study Placebo/Statin.

References

    1. Mendis S, Puska P, Norrving B; World Health Organization . Global Atlas on Cardiovascular Disease Prevention and Control: Policies, Strategies, and Interventions Geneva: World Health Organization; 2011.
    1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–952. - PubMed
    1. Expert Panel on Detection , Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497. - PubMed
    1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–2398. - PubMed
    1. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA. 2010;303:1841–1847. - PubMed

MeSH terms

LinkOut - more resources